Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Lewis Cantley
Weill Medical Coll of Cornell Univ, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Novartis Pharmaceuticals
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Dr. Cantley serves as ad hoc consul for Novartis, a pharmaceutical company that makes PI3K inhibitors.
The Role of PI3K in Growth Regulation
Defects in insulin-dependent stimulation of Phosphoinositide 3-Kinase (PI3K) result in insulin resistance and type 2 diabetes while activating mutations in PI3K result in cancers. More than twenty investigational drugs that target PI3K are currently in cancer clinical trials. The goal of this grant is to understand how PI3K is activated by insulin an growth factors and to determine how mutations in the gene encoding PI3K cause cancer.
Filed on July 21, 2014.
Tell us what you know about Lewis Cantley's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Lewis Cantley”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Lewis Cantley | Brigham and Women's Hospital | Conflict of Interest | Petra Pharmaceuticals | $100,000 - $149,999 |
| Lewis Cantley | Brigham and Women's Hospital | Conflict of Interest | Petra Pharmaceuticals | $250,000 - $299,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.